Organization Profile

You just read:

Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada

News provided by

Alnylam Pharmaceuticals, Inc.

Jul 23, 2019, 07:00 ET